-
Alvotech and Advanz Pharma receive UK MHRA marketing approval for Gobivaz
08 Nov 2025 06:50 GMT
… the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondylarthritis, ulcerative colitis in … Alvotech and Advanz Pharma, Alvotech is responsible for the development and commercial …
-
Alvotech and Advanz Pharma Secure UK Approval for Gobivaz, a Biosimilar to Simponi
07 Nov 2025 21:33 GMT
… the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondylarthritis, ulcerative colitis in … handle the development and commercial supply of Gobivaz, while Advanz Pharma holds …
-
New Serum Biomarker Detects Ulcerative Colitis Effectively
07 Nov 2025 06:13 GMT
… and management of ulcerative colitis.
Ulcerative colitis is characterized by chronic … need for personalized medicine in treating chronic diseases. With the … precision approach could help tailor treatments to individual patients, maximizing efficacy …
-
Early biologic use may cut rehospitalization risk in immune checkpoint inhibitor colitis
07 Nov 2025 03:59 GMT
… of rehospitalization following ICI colitis for the same indication,” … importance for a sustained treatment response prior to discharge … research support from Takeda Pharmaceuticals. Please see the study … Clinical Guidance, Healio CME, FDA news
Healio's …
-
C-Reactive Protein in Immune Checkpoint Inhibitor-Associated Colitis: A Scoping Review of Evidence and Knowledge Gaps
07 Nov 2025 00:34 GMT
… and often requires immunosuppressive treatment, such as corticosteroids or … reported that patients who developed colitis during ICI therapy had … Ltd., 3H Clinical Trial Inc., Novartis Pharma K.K., Pfizer Japan … inhibitors. Am J Emerg Med. 2024;80:227.e1 …
-
Protective Effect of Xihuang Pill on Immune Checkpoint Inhibitors-Related Myocarditis in a Mouse Model by Regulating the HIF-1 Signaling Pathway
07 Nov 2025 00:34 GMT
… angiopoietins crucial for vascular development and angiogenesis. Angpt2, … novel strategy for treating ICIs-induced cardiac … in Prevention and Treatment. Pharmacogenomics Personalized Med. 2023;16:1067 … et al. Xihuang pill ameliorates colitis in mice by …
-
Alvotech, Advanz Pharma Receive MHRA Marketing Authorizations for Gobivaz
06 Nov 2025 16:03 GMT
… the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondylarthritis, ulcerative colitis in … Alvotech and Advanz Pharma, Alvotech is responsible for the development and commercial …
-
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06 Nov 2025 14:07 GMT
… treatment of rheumatoid arthritis, psoriatic arthritis, axial spondylarthritis, ulcerative colitis … Advanz Pharma, Alvotech is responsible for the development … candidates aimed at treating autoimmune disorders, eye … responses to the FDA’s inspection findings …
-
<![CDATA[FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy]]>
06 Nov 2025 04:19 GMT
… living with ulcerative colitis."
Treatment with mirikizumab for … inflammation. The drug received its first FDA approval in … treatment for moderately to severely active ulcerative colitis. In January 2025, the FDA … 3 VIVID-1 trial demonstrated that 53% …
-
New method brings hope for personalized treatment of inflammatory bowel disease
06 Nov 2025 01:08 GMT
… ’s disease and ulcerative colitis.
These disorders are affecting … more medications has improved in recent years, but the drugs … indicate the likelihood that a drug will work.
“Many … treatment for each patient,” says Haukaas.
The method can also help develop …
About
© 1995-2025